Impact of glucocorticoids on insulin resistance in the critically ill

Christopher Pretty, J. Geoffrey Chase, Jessica Lin, Geoffrey M. Shaw, Aaron Le Compte, Normy Norfiza Abdul Razak, Jacquelyn D. Parente

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Glucocorticoids (GCs) have been shown to reduce insulin sensitivity in healthy individuals. Widely used in critical care to treat a variety of inflammatory and allergic disorders, they may inadvertently exacerbate stress-hyperglycaemia. This research uses model-based methods to quantify the reduction in insulin sensitivity from GCs in critically ill patients, and thus their impact on glycaemic control. A model-based measure of insulin sensitivity (SI) was used to quantify changes between two matched cohorts of 40 intensive care unit (ICU) patients. Patients in one cohort received GC treatment, while patients in the control cohort did not. All patients were admitted to the Christchurch hospital ICU between 2005 and 2007 and spent at least 24h on the SPRINT glycaemic control protocol. A 31% reduction in whole-cohort median insulin sensitivity was seen between the control cohort and patients receiving glucocorticoids with a median dose equivalent to 200. mg/d of hydrocortisone per patient. Comparing percentile patients as a surrogate for matched patients, reductions in median insulin sensitivity of 20%, 25%, and 21% were observed for the 25th-, 50th- and 75th-percentile patients, respectively. These cohort and percentile patient reductions are less than or equivalent to the 30-62% reductions reported in healthy subjects especially when considering the fact that the GC doses in this study are 1.3-4.0 times larger than those in studies of healthy subjects. This reduced suppression of insulin sensitivity in critically ill patients could be a result of saturation due to already increased levels of catecholamines and cortisol common in critically illness. Virtual trial simulation showed that reductions in insulin sensitivity of 20-30% associated with glucocorticoid treatment in the ICU have limited impact on glycaemic control levels within the context of the SPRINT protocol.

Original languageEnglish
Pages (from-to)172-180
Number of pages9
JournalComputer Methods and Programs in Biomedicine
Volume102
Issue number2
DOIs
Publication statusPublished - 01 May 2011

Fingerprint

Insulin
Critical Illness
Glucocorticoids
Insulin Resistance
Intensive care units
Cortisol
Intensive Care Units
Patient treatment
Level control
Hydrocortisone
Healthy Volunteers
Critical Care
Hyperglycemia
Catecholamines

All Science Journal Classification (ASJC) codes

  • Software
  • Computer Science Applications
  • Health Informatics

Cite this

Pretty, Christopher ; Chase, J. Geoffrey ; Lin, Jessica ; Shaw, Geoffrey M. ; Le Compte, Aaron ; Abdul Razak, Normy Norfiza ; Parente, Jacquelyn D. / Impact of glucocorticoids on insulin resistance in the critically ill. In: Computer Methods and Programs in Biomedicine. 2011 ; Vol. 102, No. 2. pp. 172-180.
@article{aa10a31cb1db47a7bb7d7d883028fc06,
title = "Impact of glucocorticoids on insulin resistance in the critically ill",
abstract = "Glucocorticoids (GCs) have been shown to reduce insulin sensitivity in healthy individuals. Widely used in critical care to treat a variety of inflammatory and allergic disorders, they may inadvertently exacerbate stress-hyperglycaemia. This research uses model-based methods to quantify the reduction in insulin sensitivity from GCs in critically ill patients, and thus their impact on glycaemic control. A model-based measure of insulin sensitivity (SI) was used to quantify changes between two matched cohorts of 40 intensive care unit (ICU) patients. Patients in one cohort received GC treatment, while patients in the control cohort did not. All patients were admitted to the Christchurch hospital ICU between 2005 and 2007 and spent at least 24h on the SPRINT glycaemic control protocol. A 31{\%} reduction in whole-cohort median insulin sensitivity was seen between the control cohort and patients receiving glucocorticoids with a median dose equivalent to 200. mg/d of hydrocortisone per patient. Comparing percentile patients as a surrogate for matched patients, reductions in median insulin sensitivity of 20{\%}, 25{\%}, and 21{\%} were observed for the 25th-, 50th- and 75th-percentile patients, respectively. These cohort and percentile patient reductions are less than or equivalent to the 30-62{\%} reductions reported in healthy subjects especially when considering the fact that the GC doses in this study are 1.3-4.0 times larger than those in studies of healthy subjects. This reduced suppression of insulin sensitivity in critically ill patients could be a result of saturation due to already increased levels of catecholamines and cortisol common in critically illness. Virtual trial simulation showed that reductions in insulin sensitivity of 20-30{\%} associated with glucocorticoid treatment in the ICU have limited impact on glycaemic control levels within the context of the SPRINT protocol.",
author = "Christopher Pretty and Chase, {J. Geoffrey} and Jessica Lin and Shaw, {Geoffrey M.} and {Le Compte}, Aaron and {Abdul Razak}, {Normy Norfiza} and Parente, {Jacquelyn D.}",
year = "2011",
month = "5",
day = "1",
doi = "10.1016/j.cmpb.2010.08.004",
language = "English",
volume = "102",
pages = "172--180",
journal = "Computer Methods and Programs in Biomedicine",
issn = "0169-2607",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Impact of glucocorticoids on insulin resistance in the critically ill. / Pretty, Christopher; Chase, J. Geoffrey; Lin, Jessica; Shaw, Geoffrey M.; Le Compte, Aaron; Abdul Razak, Normy Norfiza; Parente, Jacquelyn D.

In: Computer Methods and Programs in Biomedicine, Vol. 102, No. 2, 01.05.2011, p. 172-180.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of glucocorticoids on insulin resistance in the critically ill

AU - Pretty, Christopher

AU - Chase, J. Geoffrey

AU - Lin, Jessica

AU - Shaw, Geoffrey M.

AU - Le Compte, Aaron

AU - Abdul Razak, Normy Norfiza

AU - Parente, Jacquelyn D.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Glucocorticoids (GCs) have been shown to reduce insulin sensitivity in healthy individuals. Widely used in critical care to treat a variety of inflammatory and allergic disorders, they may inadvertently exacerbate stress-hyperglycaemia. This research uses model-based methods to quantify the reduction in insulin sensitivity from GCs in critically ill patients, and thus their impact on glycaemic control. A model-based measure of insulin sensitivity (SI) was used to quantify changes between two matched cohorts of 40 intensive care unit (ICU) patients. Patients in one cohort received GC treatment, while patients in the control cohort did not. All patients were admitted to the Christchurch hospital ICU between 2005 and 2007 and spent at least 24h on the SPRINT glycaemic control protocol. A 31% reduction in whole-cohort median insulin sensitivity was seen between the control cohort and patients receiving glucocorticoids with a median dose equivalent to 200. mg/d of hydrocortisone per patient. Comparing percentile patients as a surrogate for matched patients, reductions in median insulin sensitivity of 20%, 25%, and 21% were observed for the 25th-, 50th- and 75th-percentile patients, respectively. These cohort and percentile patient reductions are less than or equivalent to the 30-62% reductions reported in healthy subjects especially when considering the fact that the GC doses in this study are 1.3-4.0 times larger than those in studies of healthy subjects. This reduced suppression of insulin sensitivity in critically ill patients could be a result of saturation due to already increased levels of catecholamines and cortisol common in critically illness. Virtual trial simulation showed that reductions in insulin sensitivity of 20-30% associated with glucocorticoid treatment in the ICU have limited impact on glycaemic control levels within the context of the SPRINT protocol.

AB - Glucocorticoids (GCs) have been shown to reduce insulin sensitivity in healthy individuals. Widely used in critical care to treat a variety of inflammatory and allergic disorders, they may inadvertently exacerbate stress-hyperglycaemia. This research uses model-based methods to quantify the reduction in insulin sensitivity from GCs in critically ill patients, and thus their impact on glycaemic control. A model-based measure of insulin sensitivity (SI) was used to quantify changes between two matched cohorts of 40 intensive care unit (ICU) patients. Patients in one cohort received GC treatment, while patients in the control cohort did not. All patients were admitted to the Christchurch hospital ICU between 2005 and 2007 and spent at least 24h on the SPRINT glycaemic control protocol. A 31% reduction in whole-cohort median insulin sensitivity was seen between the control cohort and patients receiving glucocorticoids with a median dose equivalent to 200. mg/d of hydrocortisone per patient. Comparing percentile patients as a surrogate for matched patients, reductions in median insulin sensitivity of 20%, 25%, and 21% were observed for the 25th-, 50th- and 75th-percentile patients, respectively. These cohort and percentile patient reductions are less than or equivalent to the 30-62% reductions reported in healthy subjects especially when considering the fact that the GC doses in this study are 1.3-4.0 times larger than those in studies of healthy subjects. This reduced suppression of insulin sensitivity in critically ill patients could be a result of saturation due to already increased levels of catecholamines and cortisol common in critically illness. Virtual trial simulation showed that reductions in insulin sensitivity of 20-30% associated with glucocorticoid treatment in the ICU have limited impact on glycaemic control levels within the context of the SPRINT protocol.

UR - http://www.scopus.com/inward/record.url?scp=79955158672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955158672&partnerID=8YFLogxK

U2 - 10.1016/j.cmpb.2010.08.004

DO - 10.1016/j.cmpb.2010.08.004

M3 - Article

VL - 102

SP - 172

EP - 180

JO - Computer Methods and Programs in Biomedicine

JF - Computer Methods and Programs in Biomedicine

SN - 0169-2607

IS - 2

ER -